HOME >> BIOLOGY >> NEWS
Other highlights in the September 21 JNCI

Study Reports Elevated Risk of Second Cancers for Testicular Cancer Survivors

Men who survive testicular cancer have an increased risk of developing a second cancer for at least 35 years after diagnosis, according to the largest study to date of testicular cancer survivors.

Testicular cancer largely affects young men, and the 10-year survival rate of the disease is as high as 95%, so most men survive testicular cancer. However, these men have an increased risk of developing second cancers, mostly because of the late side effects of treatment. These cancers are a leading cause of death for testicular cancer patients.

To determine the risks of second cancers among long-term survivors of testicular cancer, Lois B. Travis, M.D., of the National Cancer Institute, and colleagues examined data from 40,576 1-year survivors of testicular cancer from population-based tumor registries in Europe and North America. A total of 2,285 second solid cancers were reported among these men anywhere from 1 year to more than 35 years after their testicular cancer diagnosis.

Ten-year survivors who had been diagnosed with testicular cancer at age 35 had a risk of developing a second cancer that was nearly twice that of the general population, and this risk remained elevated for 35 years. Risks were higher for patients diagnosed with testicular cancer at younger ages and lower for patients diagnosed at older ages. Cancers of the bladder, colon, lung, pancreas, and stomach accounted for 60% of the total excess risk. The authors conclude that testicular cancer survivors are at increased risk of solid tumors for at least 35 years after treatment and that young patients may face high levels of risk as they get older.

Contact: National Cancer Institute Press Office, 301-496-6641, NCIPressOfficers@mail.nih.gov

Hormone Replacement Therapy Associated With Increases in Mammographic Breast Den
'"/>

Contact: Sarah L. Zielinski
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
20-Sep-2005


Page: 1 2 3 4 5

Related biology news :

1. Other highlights in the Aug. 7 JNCI
2. Other highlights in the July 24 JNCI
3. Other highlights from the July 10 JNCI
4. Other highlights in JNCI, June 26
5. Other highlights in JNCI, June 12
6. Other highlights from the June 6 JNCI
7. Other highlights in the May 16 JNCI
8. Other highlights from the April 18 Journal of the National Cancer Institute
9. Other highlights from the March 21 JNCI
10. Other highlights in the March 7 JNCI
11. Other highlights in the Feb. 21 JNCI

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Other highlights the September JNCI

(Date:10/16/2014)... 2014) – Post-menopausal women experienced improvements in vaginal ... or genital bleeding, after 12 weeks of daily ... soy germ-based nutritional supplement previously shown to help ... peer-reviewed pilot study reported in a poster at ... meeting. , "These data documented improved vaginal ...
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
Cached News: